224 related articles for article (PubMed ID: 18719068)
1. Screening and management of osteoporosis in breast cancer patients on aromatase inhibitors.
Gibson K; O'Bryant CL
J Oncol Pharm Pract; 2008 Sep; 14(3):139-45. PubMed ID: 18719068
[TBL] [Abstract][Full Text] [Related]
2. Zoledronic acid for treatment of osteopenia and osteoporosis in women with primary breast cancer undergoing adjuvant aromatase inhibitor therapy: a 5-year follow-up.
Majithia N; Atherton PJ; Lafky JM; Wagner-Johnston N; Olson J; Dakhil SR; Perez EA; Loprinzi CL; Hines SL
Support Care Cancer; 2016 Mar; 24(3):1219-26. PubMed ID: 26298334
[TBL] [Abstract][Full Text] [Related]
3. Aromatase inhibitor-induced bone mineral loss and its prevention by bisphosphonate administration in postmenopausal breast cancer patients.
Yonehara Y; Iwamoto I; Kosha S; Rai Y; Sagara Y; Douchi T
J Obstet Gynaecol Res; 2007 Oct; 33(5):696-9. PubMed ID: 17845332
[TBL] [Abstract][Full Text] [Related]
4. Risks of osteoporosis associated with breast cancer treatment: the need to access to preventive treatment.
Rozenberg S; Carly B; Liebens F; Antoine C
Maturitas; 2009 Sep; 64(1):1-3. PubMed ID: 19709824
[TBL] [Abstract][Full Text] [Related]
5. Osteoporosis therapy and outcomes for postmenopausal patients with hormone receptor-positive breast cancer: NCIC CTG MA.27.
Lipton A; Chapman JW; Leitzel K; Garg A; Pritchard KI; Ingle JN; Budd GT; Ellis MJ; Sledge GW; Rabaglio M; Han L; Elliott CR; Shepherd LE; Goss PE; Ali SM
Cancer; 2017 Jul; 123(13):2444-2451. PubMed ID: 28464211
[TBL] [Abstract][Full Text] [Related]
6. Emerging bone health issues in women with breast cancer in Hawai'i.
Carney JF; Davis J
Hawaii Med J; 2007 Jun; 66(6):164-6. PubMed ID: 17621865
[TBL] [Abstract][Full Text] [Related]
7. Prevalence of secondary causes of bone loss among breast cancer patients with osteopenia and osteoporosis.
Camacho PM; Dayal AS; Diaz JL; Nabhan FA; Agarwal M; Norton JG; Robinson PA; Albain KS
J Clin Oncol; 2008 Nov; 26(33):5380-5. PubMed ID: 18955450
[TBL] [Abstract][Full Text] [Related]
8. Impact of aromatase inhibitors on bone health in breast cancer patients.
Geisler J; Lønning PE
J Steroid Biochem Mol Biol; 2010 Feb; 118(4-5):294-9. PubMed ID: 19833206
[TBL] [Abstract][Full Text] [Related]
9. Bone health management of Australian breast cancer survivors receiving hormonal therapy.
Roberts R; Miller M; O'Callaghan M; Koczwara B
Intern Med J; 2015 Nov; 45(11):1182-5. PubMed ID: 26348867
[TBL] [Abstract][Full Text] [Related]
10. Adjuvant aromatase inhibitors and bone health.
Chowdhury S; Pickering LM; Ellis PA
J Br Menopause Soc; 2006 Sep; 12(3):97-103. PubMed ID: 16953982
[TBL] [Abstract][Full Text] [Related]
11. Androgens and musculoskeletal symptoms among breast cancer patients on aromatase inhibitor therapy.
Gallicchio L; Macdonald R; Wood B; Rushovich E; Helzlsouer KJ
Breast Cancer Res Treat; 2011 Nov; 130(2):569-77. PubMed ID: 21647676
[TBL] [Abstract][Full Text] [Related]
12. Bone health and adherence to vitamin D and calcium therapy in early breast cancer patients on endocrine therapy with aromatase inhibitors.
Bošković L; Gašparić M; Petković M; Gugić D; Lovasić IB; Soldić Ž; Miše BP; Dabelić N; Vazdar L; Vrdoljak E
Breast; 2017 Feb; 31():16-19. PubMed ID: 27810693
[TBL] [Abstract][Full Text] [Related]
13. Aromatase inhibitors and bone health in women with breast cancer.
Chien AJ; Goss PE
J Clin Oncol; 2006 Nov; 24(33):5305-12. PubMed ID: 17114665
[No Abstract] [Full Text] [Related]
14. Guidance for the management of breast cancer treatment-induced bone loss: a consensus position statement from a UK Expert Group.
Reid DM; Doughty J; Eastell R; Heys SD; Howell A; McCloskey EV; Powles T; Selby P; Coleman RE
Cancer Treat Rev; 2008; 34 Suppl 1():S3-18. PubMed ID: 18515009
[TBL] [Abstract][Full Text] [Related]
15. Incidence and management of arthralgias in breast cancer patients treated with aromatase inhibitors in an outpatient oncology clinic.
Menas P; Merkel D; Hui W; Lawton J; Harper A; Carro G
J Oncol Pharm Pract; 2012 Dec; 18(4):387-93. PubMed ID: 22277833
[TBL] [Abstract][Full Text] [Related]
16. Zoledronic acid effectively prevents aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole: Z-FAST study 36-month follow-up results.
Brufsky AM; Bosserman LD; Caradonna RR; Haley BB; Jones CM; Moore HC; Jin L; Warsi GM; Ericson SG; Perez EA
Clin Breast Cancer; 2009 May; 9(2):77-85. PubMed ID: 19433387
[TBL] [Abstract][Full Text] [Related]
17. Effect of calcitonin on anastrozole-induced bone pain during aromatase inhibitor therapy for breast cancer.
Liu P; Yang DQ; Xie F; Zhou B; Liu M
Genet Mol Res; 2014 Jul; 13(3):5285-91. PubMed ID: 25078584
[TBL] [Abstract][Full Text] [Related]
18. Cost-effectiveness of dual-energy X-ray absorptiometry plus antiresorptive treatment in Australian women with breast cancer who receive aromatase inhibitors.
Sowa PM; Downes MJ; Gordon LG
J Bone Miner Metab; 2017 Mar; 35(2):199-208. PubMed ID: 26969395
[TBL] [Abstract][Full Text] [Related]
19. Prevention of osteoporosis after breast cancer.
Reid DM
Maturitas; 2009 Sep; 64(1):4-8. PubMed ID: 19709826
[TBL] [Abstract][Full Text] [Related]
20. Integrated analysis of zoledronic acid for prevention of aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole.
Brufsky A; Bundred N; Coleman R; Lambert-Falls R; Mena R; Hadji P; Jin L; Schenk N; Ericson S; Perez EA;
Oncologist; 2008 May; 13(5):503-14. PubMed ID: 18515735
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
